Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Presentation TCT 2020

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

Presenter: Robert Yeh

October 14, 2020

Presentation TCT 2019

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Presenter: Ajay Kirtane

September 28, 2019

Presentation TCT 2019

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

Presenter: Ajay Kirtane

September 27, 2019

Presentation TCT 2019

EVOLVE/ LEADERS Short DAPT Programs

Presenter: Ajay Kirtane

September 27, 2019

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

Caitlin E. Cox

September 26, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

Presentation TCT 2019

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Presenter: Ajay Kirtane

September 26, 2019

Presentation TCT 2018

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

Presenter: Dominick J. Angiolillo, Neal S. Kleiman, Ajay J. Kirtane

September 24, 2018

News Conference News TCT 2017

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Shelley Wood

October 20, 2017

Video

» Interview

Dr. C. Michael Gibson Talks With Dr. Ajay Kirtane About EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

September 29, 2019

Advertisement

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

The Evolving SYNERGY Programs: EVOLVE-Short DAPT Updates

Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science

EVOLVE/ LEADERS Short DAPT Programs

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent

TCT 2017: High Hopes in Denver for Complex PCI, Shorter DAPT Durations, TAVR Costs, and More

Dr. C. Michael Gibson Talks With Dr. Ajay Kirtane About EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated a Bioabsorbable Polymer-Based Everolimus-Eluting Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content